guidelines on variations to a registered pharmaceutical product

Guidelines on Variations to a Registered Pharmaceutical Product3. The manufacturing processes for the currently accepted and proposed products use the sameprinciples (e.g. a change from wet to dry granulation, from direct compression to wet/dry granulation orvice versa would be considered a change in manufacturing principle), same processing intermediatesand there are no changes to any manufacturing solvent used in the process.4. The same classes of equipment, operating procedures, in-process controls (no widening or deletingof limits) are used for the currently accepted and proposed products; no change in critical processparameters.5. No change in the specifications of the intermediates or the FPP.6. The change is not necessitated by unexpected events, resulting in failure to meet specifications,arising during manufacture or because of stability concerns.7. The change does not involve packaging or labeling where the primary packaging provides a meteringand/or delivery function.8. The change does not concern a gastro-resistant, modified or prolonged release FPP.9. The change does not affect the sterilization parameters of a sterile FPP.Documentation required1. Supporting clinical or comparative bioavailability data or justification for not submitting a newbioequivalence study according to the current WHO Guidelines on Bioequivalence.2. Discussion on the development of the manufacturing process; where applicable:3. comparative in vitro testing, e.g. multipoint dissolution profiles in the release medium for solid dosageunits (one production batch and comparative data of one batch from the previous process and thebiobatch results, data on the next two production batches should be available on request or reportedif outside specification);4. comparative in vitro membrane diffusion (membrane release testing) for non-sterile semisolid dosageforms containing the API in the dissolved or non-dissolved form (one production batch and comparativedata of one batch from the previous process and the biobatch results, data on the next two productionbatches) should be submitted or be available on request;5. microscopic imaging of particles to check for visible changes in morphology and comparative sizedistribution data for liquid products in which the API is present in non-dissolved form.6. Batch formula, description of manufacturing process and process controls, controls of critical stepsand intermediates, process validation protocol and/or evaluation.7. Specification(s), certificate of analysis for one production scale batch each manufactured according tothe currently accepted and the proposed processes.8. Results of stability testing generated on at least two pilot batches (for uncomplicated products onepilot batch, the other one can be smaller) with a minimum of three (3) months of accelerated (andintermediate, as appropriate) and three (3) months of long-term testing.9. Updated post-acceptance stability protocol and stability commitment to place the first production scalebatch of the proposed product into the long-term stability programme.10. Copies of relevant sections of blank master production documents with changes highlighted as wellas executed production documentation for one batch and confirmation that there are no changes tothe currently accepted production documents other than those highlighted.Doc. No.: DAR/GDL/005 Revision Date: 8 th July 2013 Review Due Date: 16 th July 2016Revision No.: 1 Effective Date : 16 th July 2013 Page 45 of 70